Literature DB >> 19650250

Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature.

L Lindell-Osuagwu1, M J Korhonen, S Saano, M Helin-Tanninen, T Naaranlahti, H Kokki.   

Abstract

OBJECTIVES: In paediatric pharmacotherapy, many drugs are prescribed to be given in ways and for conditions not approved in the marketing authorization (MA). Thus, off-label prescribing of drugs with no MA is widespread in paediatric wards. However, drug MA status and clinical practices differ across countries. In this prospective study, we studied the prescribing of off-label and unlicensed drugs in three paediatric wards in a tertiary hospital in Finland. Furthermore, we reviewed previous published studies to provide an up-to-date international perspective on prescribing of off-label and unlicensed drugs for hospitalized children.
METHODS: During a 2-week period, prescriptions for patients under 18 years of age (median age 1*6 years) in three wards; neonatal intensive care unit (NICU), general paediatric ward and paediatric surgical ward were recorded daily and drug-licensing status of all prescriptions was determined according to the approved summary of product characteristics. Published studies were retrieved through electronic searches, including MEDLINE (PubMed).
RESULTS: Of the 141 children, 108 received 629 prescriptions. Of the 108 children with a prescription, 82 (76%) had at least one off-label or unlicensed drug prescribed; 79% in the NICU, 63% in the general ward and 91% in the surgical ward (P = 0*014). Of the 108 children with a prescription, 26 (24%) received prescriptions for licensed drugs, 71 (66%) received prescriptions off-label and 36 (33%) for unlicensed drugs. Of all 629 prescriptions, 321 (51%) were for licensed drugs, 226 (36%) for off-label and 82 (13%) for unlicensed drugs. International studies showed similar extents of off-label and unlicensed-drug prescribing.
CONCLUSION: This study indicates that the use of off-label and unlicensed drugs is widespread in all the different paediatric wards surveyed and was as extensive as those reported for other countries.

Entities:  

Mesh:

Year:  2009        PMID: 19650250     DOI: 10.1111/j.1365-2710.2008.01005.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  51 in total

1.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

Review 2.  Awareness, knowledge and views of off-label prescribing in children: a systematic review.

Authors:  S Balan; M A Hassali; V S L Mak
Journal:  Br J Clin Pharmacol       Date:  2015-11-06       Impact factor: 4.335

3.  Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic.

Authors:  Eva Skovslund Nielsen; Maja Hellfritzsch; Merete Juul Sørensen; Helle Rasmussen; Per Hove Thomsen; Torben Laursen
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-02-28       Impact factor: 4.785

Review 4.  Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the Society for Pediatric Radiology (SPR) and the International Contrast Ultrasound Society (ICUS).

Authors:  Kassa Darge; Frederica Papadopoulou; Aikaterini Ntoulia; Dorothy I Bulas; Brian D Coley; Lynn A Fordham; Harriet J Paltiel; Beth McCarville; Frank M Volberg; David O Cosgrove; Barry B Goldberg; Stephanie R Wilson; Steven B Feinstein
Journal:  Pediatr Radiol       Date:  2013-07-11

Review 5.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

6.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

7.  Unlicensed and Off-Label Drug Use in Children Before and After Pediatric Governmental Initiatives.

Authors:  Jennifer Corny; Denis Lebel; Benoit Bailey; Jean-François Bussières
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

8.  Drug utilization pattern in an Omani pediatric population.

Authors:  K A Al Balushi; F Al-Sawafi; F Al-Ghafri; I Al-Zakwani
Journal:  J Basic Clin Pharm       Date:  2013-06

9.  Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.

Authors:  Shivani V Gandhi; William Rodriguez; Mansoor Khan; James E Polli
Journal:  AAPS PharmSciTech       Date:  2014-02-21       Impact factor: 3.246

10.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.